Translational Research in Oncology
Translational Research in Oncology (TRIO) is a pioneering organisation headquartered in the vibrant city of London, with significant operations across Europe and North America. Founded in 2010, TRIO has established itself as a leader in the oncology research sector, focusing on the development of innovative clinical trials that bridge the gap between laboratory discoveries and patient care. Specialising in biomarker-driven studies, TRIO offers unique services that enhance the precision of cancer treatments. Their commitment to advancing personalised medicine has positioned them at the forefront of the industry, with notable achievements in collaborative research and successful trial outcomes. As a key player in translational oncology, TRIO continues to shape the future of cancer treatment through its dedication to scientific excellence and patient-centric approaches.
DitchCarbon Score
How does Translational Research in Oncology's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Development industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Translational Research in Oncology's score of 23 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Translational Research in Oncology's reported carbon emissions
Translational Research in Oncology currently does not have available carbon emissions data, as no specific figures have been reported. Additionally, there are no documented reduction targets or initiatives outlined in their climate commitments. This absence of data suggests that the organisation may still be in the early stages of developing a comprehensive strategy to address carbon emissions and climate impact. As the field of oncology research increasingly prioritises sustainability, it is essential for organisations like Translational Research in Oncology to establish clear climate commitments and measurable targets to contribute effectively to global efforts in reducing greenhouse gas emissions.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Translational Research in Oncology is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
